The Meeting of the Transparency Council No. 4/2023 of 23.01.2023

The agenda includes:

Preparation of evaluation positions:

• Apexxnar, pneumococcal polysaccharide conjugated vaccine (20-valent, adsorbed) for the indication: prevention of pneumococcal infections in adults over 65 years of age,|
• Lorviqua (lorlatinib) under the drug programme “First-line treatment of non-small cell lung cancer with lorlatinib (ICD-10 C 34)”.

Preparing an opinion on the legitimacy of introducing changes in the current description of the B.90 drug programme: “Treatment of motor impairment in advanced Parkinson’s disease (ICD-10 G.20)”.

Preparation of an opinion on the inclusion in the reimbursement procedure of drugs containing the active substance stiripentol for the indication: malignant focal migratory epilepsy of infants.